Psychedelic-Assisted Therapy in Palliative Care-Insights from an International Workshop.
Anna Schuldt, Ian C. Clark, Yasmin Schmid, Michael Ljuslin, Christopher Boehlke, Sivan Schipper, Megan B. Sands, David Blum
Healthcare September 12, 2025 DOI: 10.3390/healthcare13182275 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Qualitative study Peer reviewed |
|---|---|
| Sample size | 13 |
| Population | Experts in palliative care, oncology, psychiatry/psychology, and psychedelic-assisted therapy from Europe, the United States, and Oceania |
| Intervention | Psychedelic-assisted therapy |
| Topics | Psychedelic-assisted therapy End-of-life distress |
| Keywords | Psychedelics Psychedelic-assisted treatment Entheogenic therapy Mind-altering drug therapy Palliative care End-of-life care Hospice care Comfort care Serious illness support Symptom management Mental health Spiritual well-being Emotional health Psychological health Distress relief Anxiety reduction Emerging therapies Innovative treatments Novel interventions Future medicine Medical advancements |
| Citations | 1 |
| Key findings | Experts highlighted special considerations for psychedelic-assisted therapy in palliative care, including a non-medicalized setting, reduced preparation time, and flexible dosing based on patient focus. |
Abstract
Background: Evidence is growing that psychedelic substances have positive effects in the setting of Palliative Care (PC), focusing on special needs in this patient population. After a scoping review of the literature, no published expert recommendations guiding best practice for psychedelic-assisted therapy (PAT) towards the end of life were identified.
Objective: To draw conclusions from first-hand experienced professionals on PAT in PC (PATPC). Setting, Design,
Participants: An international workshop with experts was held in Wasserfallen, Switzerland. A thematic analysis of a semi-structured, questionnaire-based qualitative study with 13 experts in PC, oncology, psychiatry/psychology, and PAT from Europe, the United States, and Oceania was made.
Measurements: The questionnaire was designed to elicit the participant’s perspectives on (A) special considerations on PATPC, (B) specific characteristics of PATPC (versus mental illness), and (C) the relevance of these differences during preparation, substance dosing session, and integration in PATPC.
Results: (A) Special Considerations included (non-medicalized) setting, potential need, and possibility to reduce preparation time. (B) Distinguishing characteristics included the patient’s intrinsic motivation for treatment success, the importance of anxiety, depression, and spiritual distress as indications for PATPC, and the importance of sufficient integration of the psychedelic experience into life in the face of limited time due to the life-limiting illness. (C) Flexibility in setting and timing of preparation, choosing the appropriate dosage of the psychedelic substance depending on the patient’s intended focus, low/medium (relational issues), higher for transcendental experiences, considering mental capacity and vulnerability for the individual. In addition, respondents noted that for therapists, knowledge about transcendental states, such as mystical experiences, existential aspects of life-threatening illness, and the role of therapists’ own self-experience/inner work, as well as good knowledge of the theoretical basis for treatment, was highlighted.
Conclusions: This study highlights special considerations for PAT PC and could be a first step towards specific treatment recommendations (guidelines) for PATPC.
Comparable studies
Other qualitative studies on end-of-life distress, most cited first.
Citations in the library
Cites 20
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Archives of General Psychiatry September 7, 2010
- Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases The Journal of Nervous and Mental Disease March 4, 2014
- LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects Journal of Psychopharmacology November 11, 2014
and 15 more in the library